Role of imaging biomarkers in mutation-driven non-small cell lung cancer

doi:10.5306/wjco.v11.i7.412

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7583)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-4) series.

Item

Count

PDF

401

WORD

186

HTML

3506

Figures (1-7)

479

Tables (1-4)

266

Sum=4838

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

296

Download

563

Sum=859

Publishing Process of This Article

Item

Count

Browse

722

Download

1164

Sum=1886

Jul 24, 2020 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jul 24, 2020; 11(7): 412-427
Published online Jul 24, 2020. doi: 10.5306/wjco.v11.i7.412

Full Size Figure Download Figure

Figure 1 Comparison of select primary tumor features and metastatic patterns among patients with non-small cell lung cancer with ALK, ROS1, or EGFR alterations[71].

Citation: Mendoza DP, Piotrowska Z, Lennerz JK, Digumarthy SR. Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World J Clin Oncol 2020; 11(7): 412-427
URL: https://www.wjgnet.com/2218-4333/full/v11/i7/412.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i7.412